ACS Updates Guidelines for Cervical Cancer Screening

The new guidelines suggest the need to phase out cotesting and cytology, shifting towards primary HPV testing starting at age 25 years.

The American Cancer Society (ACS) recently released updated guidelines for cervical cancer screening, recommending that screening begin at age 25 years rather than 21 years.

The updated guidelines also recommend that, when available, primary human papillomavirus (HPV) testing should start at age 25 years rather than 30 years. Even further, it was advised that cotesting and cytology should be phased out once full access to primary HPV testing for cervical cancer screening is available without barriers.

“It is expected that the availability and use of primary HPV testing for cervical cancer screening will increase in all health care settings in the United States; but, in the meantime, screening utilization and adherence are prioritized, thus continuing the use of cytology and cotesting is acceptable if primary HPV testing is not available,” the ACS wrote in update.

Additional updates to the guidelines included that individuals older than age 65 with a cervix stop being screened as long as they have had 10 years of regular screening with normal results. Otherwise, they should continue to be screened until they do.

With regard to those who have had their cervix removed, ACS suggests there is no need for screening as long as the cervix was removed for reasons not related to cervical cancer or serious precancer.

However, the new recommendations have been viewed as controversial, with some gynecologists expressing concerns that phasing out cotesting and cytology could result in missed cancers.

In an interview with CancerNetwork®, Michael D. Randell, MD, FACOG, an obstetrics and gynecology specialist with OGBYN Atlanta (an affiliate of Emory Saint Joseph’s Hospital), spoke about his apprehension towards the new guidelines and what he recommends for his patients.

This segment comes from the CancerNetwork® portion of the MJH Life Sciences Medical World News, airing daily on all MJH Life Sciences channels.


Fontham ETH, Wolf AMD, Church TR, et al. Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society. CA: A Cancer Journal for Clinicians. doi: 10.3322/caac.21628.

Related Videos
Following the results of the phase 3 CALLA trial, Jyoti S. Mayadev, MD, discusses the importance of global clinical multidisciplinary efforts in the locally advanced cervical cancer space.
The randomized, placebo-controlled, double-blind phase 3 CALLA trial assessed the combination of durvalumab and chemoradiotherapy vs placebo and chemoradiotherapy.
Findings from the phase 3 CALLA trial indicated that intensity modulated radiation therapy was administered in 88.1% of patients with high-risk locally advanced cervical cancer treated with durvalumab and chemoradiotherapy vs 88.1% with placebo and chemoradiotherapy.
Jyoti S. Mayadev, MD, indicated that durvalumab (Imfinzi) plus chemotherapy resulted in low rates of high-grade late-onset toxicities in the phase 3 CALLA trial, which may be due in part to the quality of the technology employed during the study.
Jyoti S. Mayadev, MD, indicated that future research for cervical cancer will be focused on combination immune checkpoint inhibitors and biomarker research.
Durvalumab appeared to have no impact on the ability to deliver safe and timely radiation therapy to patients with high-risk locally advanced cervical cancer, according to Jyoti S. Mayadev, MD.
The 12-month progression-free survival rates among patients with high-risk locally advanced cervical cancer were comparable with durvalumab plus chemoradiotherapy vs placebo plus radiotherapy.
Cervical Cancer
Related Content